WaveMan
WaveMan · Company
PDSB · Pds Biotechnology Corp
> Search tickers & screens ⌘K
LIVE
← All companies

PDSB PDS Biotechnology (PDSB) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001472091
Quote by TradingView
Activist 13D
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
27
13F, latest reported quarter

What the filings say about PDSB

Activist stakes (13D), 180 days
1 filing
Largest: 19.9% of the class

PDS Biotechnology insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for PDS Biotechnology Corp in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Freitag Gregory Gene
Director
BUY
2025-03-03 SECtraded 2025-02-28
15,060
$25.0K
-17.4%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 24.6% of the 61,213 shares held after it.
  • 1 other insider bought within 30 days.
  • 27 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Freitag Gregory Gene bought about $25.0K of PDSB on Feb 28, 2025, the largest insider purchase at the company on our record; 1 other insider bought within 30 days and 27 funds added in the latest 13F quarter.
Glover Stephen C.
Director
BUY
2025-03-03 SECtraded 2025-02-28
15,061
$25.0K
-17.4%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 19.1% of the 78,851 shares held after it.
  • 1 other insider bought within 30 days.
  • 27 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Glover Stephen C. bought about $25.0K of PDSB on Feb 28, 2025, the largest insider purchase at the company on our record; 1 other insider bought within 30 days and 27 funds added in the latest 13F quarter.
HILL MATTHEW C
Chief Financial Officer
BUY
2021-12-14 SECtraded 2021-12-13
2,500
$22.5K
-88.1%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 71.9% of the 3,475 shares held after it.
  • No other insider bought within 30 days.
  • 27 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer HILL MATTHEW C bought about $22.5K of PDSB on Dec 13, 2021, the largest insider purchase at the company on our record; 27 funds added in the latest 13F quarter.
HILL MATTHEW C
Chief Financial Officer
BUY
2021-12-14 SECtraded 2021-12-13
400
$3.6K
-88.1%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 10.3% of the 3,875 shares held after it.
  • No other insider bought within 30 days.
  • 27 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer HILL MATTHEW C bought about $3.6K of PDSB on Dec 13, 2021, the largest insider purchase at the company on our record; 27 funds added in the latest 13F quarter.
HILL MATTHEW C
Chief Financial Officer
BUY
2021-12-14 SECtraded 2021-12-13
100
$900
-88.1%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 2.5% of the 4,075 shares held after it.
  • No other insider bought within 30 days.
  • 27 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer HILL MATTHEW C bought about $900 of PDSB on Dec 13, 2021, the largest insider purchase at the company on our record; 27 funds added in the latest 13F quarter.
5 transactions on record · a thin record, read with care
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
27 funds bought in last quarter
below 63% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
7.5% of the float short (float per yahoo 2026-10-27) · 1.0 days to cover · settled 2026-10-15
more than 57% of Pharma & Biotech
The situation: each line is one rule over one dataset
Nant Capital, LLC disclosed a 5%+ stake (19.9%) in the last six months.
1 clinical trial was terminated, suspended or withdrawn in the last 90 days.
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch PDSB

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+15.8%12M
-78%-27%+23%+74%2025-102025-122026-022026-042026-062026-082026-10 2026-09-21 · Nant Capital, LLC filed a 5%+ stake (19.9%)2026-09-21 · Patrick Soon-Shiong filed a 5%+ stake (19.9%)
13D/G stake
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns PDSB: institutional holders (13F)

13F holdings, latest reported quarter
VANGUARD CAPITAL MANAGEMENT LLC
1,699,315 sh
$1.5M
Focus Partners Wealth
642,177 sh
$565.8K
Quantinno Capital Management LP
642,177 sh
$565.8K
BlackRock, Inc.
607,639 sh
$535.4K
GEODE CAPITAL MANAGEMENT, LLC
587,139 sh
$517.4K

Congress trades in PDSB

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

13D: intends to influence · 13G: passive
Nant Capital, LLC
Activist 13D · 2026-09-21
19.9%
Patrick Soon-Shiong
Activist 13D · 2026-09-21
19.9%

PDSB planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

PDSB mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
iShares Micro-Cap ETF
$167.3K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$11.3K position · as of 2026-06-30
0.0%
Fidelity Extended Market Index Fund
$315.3K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$514.5K position · as of 2026-06-30
0.0%
VANGUARD INSTITUTIONAL TOTAL STOCK MARKET INDEX FUND
$42.0K position · as of 2026-06-30
0.0%
Fidelity Series Total Market Index Fund
$95.5K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
2 registered trials, 0 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
1
Phase 2
0 active
1
Phase 3
0 active
What changed recently
Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck
2026-09-03 · Active Not Recruiting → Terminated · The study is being discontinued solely based on financial constraints and is not related to the safety of study participants, the investigational product, PDS0101, nor the conduct of the study.
Phase 3
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
An activist crossed the 5% line with declared intent.
The record shows 27 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

PDSB financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
n/a
capex not filed for the four quarters
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-544.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-136.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-219.4%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
n/a
capex not filed for the four quarters
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Operating income-$31.5M-$36.3M-$43.0M-$41.7M
Net income-$34.5M-$37.6M-$42.9M-$40.9M
EPS (diluted)-0.74-1.03-1.39-1.43
Operating cash flow-$27.8M-$35.0M-$33.6M-$25.7M
Cash$26.7M$41.7M$56.6M$73.8M
SEC XBRL, fiscal years, as known on 2026-10-28

PDSB Stock Sonar score 3/7 axes

Find similar shapesCompare

PDSB ranks highest on risk and compliance (47th percentile) and institutional and government (37th), and lowest on profitability (11th), among Pharma & Biotech peers.

Profitability
11
Inputs
  • Return on equity-544.0% · 7 pct, sector of 545
  • Return on assets-136.6% · 17 pct, sector of 691
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-219.4% · 9 pct, sector of 576
Institutional and government
37
Inputs
  • Funds adding, latest quarter27 · 37 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
47
Inputs
  • Short interest, % of float+7.5% · 47 pct, sector of 816
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
4 not measured: Financial health, Growth, Insider conviction, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

3 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

PDSB filings, in plain words

Read the full summary

1 activist Schedule 13D filing in the last 180 days declared an intent to influence the company, the largest for 19.9% of the class. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies